Cure My Disease

Don't miss your cure!

 Log in / Sign up

New shot aims to shield celiac patients from gluten damage

NCT ID NCT06807463

Ongoing Disease control Sponsor: Teva Branded Pharmaceutical Products R&D LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 28, 2026 · Updated 4 times

Summary

This study tests an injectable drug called TEV-53408 in 50 adults with celiac disease who follow a gluten-free diet. Participants will be exposed to small amounts of gluten to see if the drug can prevent intestinal damage. The trial is placebo-controlled and lasts about 86 weeks, focusing on safety and how well the drug protects the gut lining.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
TEV-53408 (injectable drug)
What this could lead to
If it works, this could point toward a treatment that helps people with celiac disease tolerate accidental gluten exposure without gut damage.
What could go wrong
This is an early Phase 2a trial with only 50 people. It may not show enough benefit or could have side effects. Success in this small study does not guarantee a future approved treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CELIAC DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

celiac disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CELIAC DISEASE

Contacts and locations

Locations

  • Teva Investigational Site 12121

    Wyoming, Michigan, 49519, United States

  • Teva Investigational Site 12122

    Ogden, Utah, 84405, United States

  • Teva Investigational Site 12123

    Lynchburg, Virginia, 24502, United States

  • Teva Investigational Site 12125

    Greenville, North Carolina, 27834, United States

  • Teva Investigational Site 12126

    Miami Lakes, Florida, 33016, United States

  • Teva Investigational Site 12127

    Winston-Salem, North Carolina, 27103, United States

  • Teva Investigational Site 12128

    New York, New York, 10032, United States

  • Teva Investigational Site 12129

    Rochester, Minnesota, 55905, United States

  • Teva Investigational Site 12130

    Atlanta, Georgia, 30328, United States

  • Teva Investigational Site 12131

    Colorado Springs, Colorado, 80907, United States

  • Teva Investigational Site 12132

    Clinton Township, Michigan, 48038, United States

  • Teva Investigational Site 12133

    Marrero, Louisiana, 70072, United States

  • Teva Investigational Site 12134

    Inverness, Florida, 34452, United States

  • Teva Investigational Site 12135

    New Port Richey, Florida, 34653, United States

  • Teva Investigational Site 12137

    Waco, Texas, 76712, United States

  • Teva Investigational Site 12138

    Murrieta, California, 92563, United States

  • Teva Investigational Site 40062

    Tampere, 33520, Finland

  • Teva Investigational Site 40063

    Helsinki, 00180, Finland

  • Teva Investigational Site 78137

    Midland, 6056, Australia

  • Teva Investigational Site 78139

    Fitzroy, 3065, Australia

  • Teva Investigational Site 78140

    Maroochydore, 4558, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.